country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-106178D

Copy Link Print Information

PMX 53 monoacetate

(Synonyms: 3D53 monoacetate)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

PMX 53 monoacetate (3D53 monoacetate) is a potent orally active CD88 (C5aR) antagonist that inhibits C5a-induced neutrophil myeloperoxide release and chemotactic activity. PMX 53 monoacetate has an IC₅₀ value of 20 nM against C5a-induced neutrophil myeloperoxide release. >The value is 22 nM, and the IC₅₀ value of the chemotactic activity is 75 nM. PMX 53 monoacetate is also an agonist of MrgX2.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 852629-88-0
Formel: C₄₉H₆₉N₁₁O₉
Molecular Weight:956.14

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

PMX 53 monoacetate Chemical Structure

CAS. Nr.: 852629-88-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität

Beschreibung

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Chemical Information

CAS. Nr. 852629-88-0
Molecular Weight 956.14
Formel C₄₉H₆₉N₁₁O₉
SMILES

CC(O)=O.O=C([C@H](NC([C@@]1([H])N(CCC1)C([C@H](CCCNC([C@@H](NC2=O)CCCNC(N)=N)=O)NC([C@@H](NC(C)=O)CC3=CC=CC=C3)=O)=O)=O)CC4CCCCC4)N[C@H]2CC5=CNC6=CC=CC=C56
Synonyms

3D53 monoacetate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (8)

All Bio/Physico-chemical AssayWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer. [Abstract]

2024 May 27;15(1):4485. PMID: 38802355
Neuron

BST2 expression at astrocyte borders promotes microglial recruitment via the C3/C3aR signaling. [Abstract]

2025 Oct 24:S0896-6273(25)00751-2. PMID: 41138733
Mol Ther

Inhibition of C5AR1 impairs osteoclast mobilization and prevents bone loss. [Abstract]

2023 Aug 2;31(8):2507-2523. PMID: 37143324

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Chemotaxis of THP1 cells toward medium without FBS (control), medium without FBS + 0.1 μg/mL of C5a (C5a), and THP1 cells pre-treated 30 min with 0.9 μg/mL PMX53 toward medium without FBS + 0.1 μg/mL C5a (PMX53 + C5a) was evaluated. After 2 h of migration, RFU (Ex/Em = 485/520 nm) was measured.

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Western blotting of phosphoS6, phosphoHSP27, phosphoERK, and the loading control β-actin of THP1 cells untreated or treated with PMX53 (0.9 μg/mL) and/or C5a for 30 min. The experiment was performed three times with similar results.

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Chemotaxis of primary monocytes isolated from WT and C5aR1^-/- mice toward medium without FBS, medium without FBS + 0.1 μg/mL of C5a (C5a). Migration of WT monocytes pre-treated for 30 min with 0.9 μg/mL PMX53 toward medium without FBS + 0.1 μg/mL C5a was also evaluated n = 4–6.

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Schematic representation of the pharmacological inhibition of C5aR1 in the DoxoR-induced senescence model. At day 0, 15-week-old mice received either vehicle or DoxoR (10 mg/kg, i.p.). From day 1 to day 30, mice received PMX53 (1 mg/kg, daily subcutaneous) or vehicle 2.

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Schematic representation of the pharmacological inhibition of C5aR1 in the DoxoR-induced senescence model. At day 0, 15-week-old mice received either vehicle or DoxoR (10 mg/kg, i.p.). From day 1 to day 30, mice received PMX53 (1 mg/kg, daily subcutaneous) or vehicle 2. Quantitative parameters and 3D representation of the cortical bone of tibiae measured by μ-CT.
Invest Ophthalmol Vis Sci

The Intracellular C5a-mtC5aR1 Axis Promotes Necroptosis in Dry Eye Through DRP1-Mediated Mitochondrial Dysfunction. [Abstract]

2026 Feb 2;67(2):35. PMID: 41705776
Int Immunopharmacol

Bulk and single-cell RNA sequencing analysis with 101 machine learning combinations reveal neutrophil extracellular trap involvement in hepatic ischemia-reperfusion injury and early allograft dysfunction. [Abstract]

2024 Apr 20:131:111874. PMID: 38493695
J Cell Commun Signal

Regulation of phosphatase and tensin homolog by complement component 5a (C5a) and its receptor (C5aR1) in lupus nephritis: A novel therapeutic target. [Abstract]

2025 Dec 19;19(4):e70055. PMID: 41426360
Justus Liebig University Giessen

2026.
Research Square Print

November 28th, 2022.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

PMX 53 monoacetate

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
Chemical Information
Publications (8)
Reinheit & Dokumentation
Verweise

1/16
1/16

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Customer Validation
Chemotaxis of THP1 cells toward medium without FBS (control), medium without FBS + 0.1 μg/mL of C5a (C5a), and THP1 cells pre-treated 30 min with 0.9 μg/mL PMX53 toward medium without FBS + 0.1 μg/mL C5a (PMX53 + C5a) was evaluated. After 2 h of migration, RFU (Ex/Em = 485/520 nm) was measured.
1/16

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Customer Validation
Western blotting of phosphoS6, phosphoHSP27, phosphoERK, and the loading control β-actin of THP1 cells untreated or treated with PMX53 (0.9 μg/mL) and/or C5a for 30 min. The experiment was performed three times with similar results.
1/16

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Customer Validation
Chemotaxis of primary monocytes isolated from WT and C5aR1^-/- mice toward medium without FBS, medium without FBS + 0.1 μg/mL of C5a (C5a). Migration of WT monocytes pre-treated for 30 min with 0.9 μg/mL PMX53 toward medium without FBS + 0.1 μg/mL C5a was also evaluated n = 4–6.
1/16

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Customer Validation
Schematic representation of the pharmacological inhibition of C5aR1 in the DoxoR-induced senescence model. At day 0, 15-week-old mice received either vehicle or DoxoR (10 mg/kg, i.p.). From day 1 to day 30, mice received PMX53 (1 mg/kg, daily subcutaneous) or vehicle 2.
1/16

PMX 53 monoacetate purchased from MedChemExpress. Usage Cited in: Mol Ther. 2023 Aug 2;31(8):2507-2523. [Abstract]

Customer Validation
Schematic representation of the pharmacological inhibition of C5aR1 in the DoxoR-induced senescence model. At day 0, 15-week-old mice received either vehicle or DoxoR (10 mg/kg, i.p.). From day 1 to day 30, mice received PMX53 (1 mg/kg, daily subcutaneous) or vehicle 2. Quantitative parameters and 3D representation of the cortical bone of tibiae measured by μ-CT.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PMX 53 monoacetate

Publications Citing Use of MedChemExpress (MCE) PMX 53 monoacetate

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

PMX 53 monoacetate Related Classifications

Art. -Nr.: HY-106178D